Detalles de la búsqueda
1.
IDH-mutant myeloid neoplasms are associated with seronegative rheumatoid arthritis and innate immune activation.
Blood
; 143(18): 1873-1877, 2024 May 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38457663
2.
Outcomes following venetoclax-based treatment in therapy-related myeloid neoplasms.
Am J Hematol
; 97(8): 1013-1022, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35560061
3.
Clinical Effectiveness of Conjugate Pneumococcal Vaccination in Hematopoietic Stem Cell Transplantation Recipients.
Biol Blood Marrow Transplant
; 26(2): 421-427, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31627016
4.
Respiratory Viruses Cause Late Morbidity in Recipients of Hematopoietic Stem Cell Transplantation.
Biol Blood Marrow Transplant
; 26(4): 782-788, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31866345
5.
TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype.
Blood
; 141(9): 1087-1091, 2023 03 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36574363
6.
The burden of immune-mediated refractoriness to platelet transfusions in myelodysplastic syndromes.
Transfusion
; 60(10): 2192-2198, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32905635
7.
Red cell alloimmunization is associated with development of autoantibodies and increased red cell transfusion requirements in myelodysplastic syndrome.
Haematologica
; 102(12): 2021-2029, 2017 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-28983058
8.
Dynamic assessment of RBC-transfusion dependency improves the prognostic value of the revised-IPSS in MDS patients.
Am J Hematol
; 92(6): 508-514, 2017 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-28247421
9.
Red cell autoimmunization and alloimmunization in myelodysplastic syndromes: prevalence, characteristic and significance.
Haematologica
; 104(10): e451-e454, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-30819906
10.
Factors predicting survival following alloSCT in patients with therapy-related AML and MDS: a multicenter study.
Bone Marrow Transplant
; 58(7): 769-776, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37012415
11.
A Personalized Risk Model for Azacitidine Outcome in Myelodysplastic Syndrome and Other Myeloid Neoplasms Identified by Machine Learning Model Utilizing Real-World Data.
Cancers (Basel)
; 15(16)2023 Aug 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37627047
12.
Allogeneic hematopoietic stem cell transplant outcomes in adults with inherited myeloid malignancies.
Blood Adv
; 7(4): 549-554, 2023 02 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-36001442
13.
TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms.
Blood Cancer J
; 13(1): 51, 2023 04 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37041128
14.
Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer.
Leukemia
; 35(11): 3245-3256, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-33850299
15.
Comprehensive geriatric assessment predicts azacitidine treatment duration and survival in older patients with myelodysplastic syndromes.
J Geriatr Oncol
; 11(1): 114-120, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31023599
16.
The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distribution.
Leukemia
; 33(12): 2842-2853, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31089247
17.
Personalized risk model for predicting risk of acute coronary syndrome in patients with myelodysplastic syndromes.
Blood Adv
; 7(13): 3032-3035, 2023 07 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36884290
18.
Screening for deficits using the G8 and VES-13 in older patients with Myelodysplastic syndromes.
J Geriatr Oncol
; 11(1): 128-130, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31053426
Resultados
1 -
18
de 18
1
Próxima >
>>